|Other names||Cystinuria-lysinuria |
|These cystine crystals were found in the urine sediment of a male dog who presented to the veterinary hospital with a history of chronic stranguria (straining to urinate) and pollakiuria (abnormally increased frequency of urination). A cystotomy was performed and numerous cystoliths (bladder stones) were removed. 5μm scale bar; 1,000x magnification; focus-stacked image consisting of 12 exposures; courtesy of Lance Wheeler.|
Cystinuria is an inherited autosomal recessive disease that is characterized by high concentrations of the amino acid cysteine in the urine, leading to the formation of cystine stones in the kidneys, ureter, and bladder. It is a type of aminoaciduria.
Cystinuria is a cause of persistent kidney stones. It is a disease involving the defective transepithelial transport of cystine and dibasic amino acids in the kidney and intestine, and is one of many causes of kidney stones. If not treated properly, the disease could cause serious damage to the kidneys and surrounding organs, and in some rare cases death. The stones may be identified by a positive nitroprusside cyanide test. The crystals are usually hexagonal, translucent, white. Upon removal, the stones may be pink or yellow in color, but later they turn to greenish due to exposure to air. Cystinuria is usually asymptomatic when no stone is formed. However, once a stone is formed, or if stone production is severe or frequent, symptoms may be present:
- Dull ache or "colicky" pain
- Chronic pain
- Obstructive syndromes like hydronephrosis
- Infective syndromes like pyelonephritis
Cystinurics can also experience chronic pain in one, or both, kidneys due to the scars that the jagged edges of the stones can leave or damage from multiple stone removal surgeries. This can leave a cystinuric in constant pain which often requires medical intervention, such as long-term use of analgesics or surgical procedures, including T11, T12 or T13 nerve blocks (although, these procedures are often not successful, they can provide some relief). Aside from the chronic pain, a cystinuric will often have severe breakthrough pain from passing stones. People with cystinuria pass stones monthly, weekly, or daily, and need ongoing care. Cystinurics have an increased risk for chronic kidney disease and since kidney damage or poor function is often present in cystinurics, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) or over the counter (OTC) medications should be used with caution.
Cystine stones are often not visible on most x-rays, CT's, and ultrasounds. This does not mean the cystinuric doesn't have a stone. It takes a trained eye and experience to spot a cystine stone. It is not unusual for a cystinuric to pass a stone, or stones, after being released from the hospital with a CT or x-ray result of no stones in the kidneys.
Urine odor in cystinuria has a smell of rotten eggs due to the increase in cystine.
Cystinuria is an autosomal recessive disease, which means that the defective gene responsible for the disease is located on an autosome, and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disease. The parents of an individual with an autosomal recessive disease both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disease. Although signs and symptoms are rare, there are some directly and indirectly associated with cystinuria. These sign and symptoms consist of 1) hematuria- blood in the urine, 2) flank pain – pain in the side due to kidney pain, 3) renal colic – intense, cramping pain due to stones in the urinary tract, 4) obstructive uropathy- urinary tract disease due to obstruction, and 5) urinary tract infections.
Cystinuria is caused by mutations in the SLC3A1 and SLC7A9 genes. These defects prevent proper reabsorption of basic, or positively charged, amino acids: cysteine, lysine, ornithine, arginine. Under normal circumstances, this protein allows certain amino acids, including cysteine, to be reabsorbed into the blood from the filtered fluid that will become urine. Mutations in either of these genes disrupt the ability of this transporter protein to reabsorb these amino acids, allowing them to become concentrated in the urine. As the levels of cysteine in the urine increase, it forms cystine crystals, resulting in kidney stones. Cystine crystals form hexagonal-shaped crystals that can be viewed upon microscopic analysis of the urine. The other amino acids that are not reabsorbed do not create crystals in urine.
Cystinuria is characterized by the inadequate reabsorption of cystine in the proximal convoluted tubules after the filtering of the amino acids by the kidney's glomeruli, thus resulting in an excessive concentration of this amino acid in the urine. Cystine may precipitate out of the urine, if the urine is neutral or acidic, and form crystals or stones in the kidneys, ureters, or bladder. It is one of several inborn errors of metabolism included in the Garrod's tetrad. The disease is attributed to deficiency in transport and metabolism of amino acids.
- Blood: Routine hemogram along with blood sugar, urea, and creatinine.
- Urine: For cystine crystals, and casts. The most specific test is the cyanide–nitroprusside test
- Ultrasound/CT scan to reveal if a stone is present.
- Genetic analysis to determine which mutation associated with the disease may be present. Currently genotyping is not available in the United States but might be available in Spain, Italy, UK, Germany and Russia (by private companies in Germany and Russia).
Regular X-rays often fail to show the cystine stones, however they can be visualized in the diagnostic procedure that is called intravenous pyelogram (or IVP for short). Stones may show up on XR with a fuzzy gray appearance. They are radioopaque due to sulfur content, though more difficult to visualize than calcium oxalate stones.
Initial treatment is with adequate hydration, alkalization of the urine with citrate supplementation or acetazolamide, and dietary modification to reduce salt and protein intake (especially methionine). If this fails then patients are usually started on chelation therapy with an agent such as penicillamine. Tiopronin is another agent. Once renal stones have formed, however, the first-line treatment is ESWL (Extracorporeal shock wave lithotripsy). If ESWL does not work efficiently, surgery may be necessary. Both endoscopic surgery and conventional open-abdominal surgery have proven to be effective treatment modalities for patients with more advanced disease. Adequate hydration is the foremost aim of treatment to prevent cysteine stones. The goal is to increase the urine volume because the concentration of cystine in the urine is reduced which prevents cystine from precipitating from the urine and forming stones. People with cystine stones should consume 5 to 7 liters a day. The rationale behind alkalizing the urine is that cystine tends to stay in solution and causes no harm. In order to alkalize the urine, sodium bicarbonate has been used. One must be careful in alkalizing their urine because it could lead to other forms of stones in process of preventing cystine stones. Penicillamine is a drug that acts to form a complex with cystine that is 50 times more soluble than cystine itself. Percutaneous nephrolithotripsy (PNL) is performed via a port created by puncturing the kidney through the skin and enlarging the access port to 1 cm in diameter. Most of the time, cystine stones are too dense to be broken up by shock (ESWL) so PNL is needed.
Videos of surgery are available on various websites that show stone removal by percutaneous nephrolithotomy.
In February 2017, an article was published in Nature Medicine entitled 'Alpha lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria', suggesting that a high dose of the readily available antioxidant, alpha-lipoic acid at 2,700 mg/67 kg body weight daily reduced the incidence of stones. The effects were dose dependent. The results are unprecedented for cystinuria. A clinical trial is underway based on this mouse model.
Occurrence in animals
This disease is known to occur in at least four mammalian species: humans, domestic canines, domestic ferrets and a wild canid, the maned wolf of South America. Cystine uroliths have been demonstrated, usually in male dogs, from approximately 70 breeds including the Australian cattle dog, Australian shepherd, Basenji, Basset, Bullmastiff, Chihuahua, Scottish deerhound, Scottish terrier, Staffordshire terrier, Welsh corgi, and both male and female Newfoundland dogs.
- "Cystinuria | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 15 April 2019.
- Fjellstedt, Erik; Harnevik, Lotta; Jeppsson, Jan-Olof; Tiselius, Hans-Göran; Söderkvist, Peter; Denneberg, Torsten (2003). "Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds". Urological Research. 31 (6): 417–25. doi:10.1007/s00240-003-0366-6. PMID 14586528.
- http://cystinuria.com/symptoms/[unreliable medical source?]
- Sarica, Kemal; Yencilek, Faruk (2008). "Prevention of shockwave induced functional and morphological alterations: An overview" (PDF). Archivio Italiano di Urologia e Andrologia. 80 (1): 27–33. PMID 18533622.
- Rule, A. D.; Krambeck, A. E.; Lieske, J. C. (2011). "Chronic Kidney Disease in Kidney Stone Formers". Clinical Journal of the American Society of Nephrology. 6 (8): 2069–75. doi:10.2215/CJN.10651110. PMC 3156433. PMID 21784825.
- Rule, A. D.; Bergstralh, E. J.; Melton, L. J.; Li, X.; Weaver, A. L.; Lieske, J. C. (2009). "Kidney Stones and the Risk for Chronic Kidney Disease". Clinical Journal of the American Society of Nephrology. 4 (4): 804–11. doi:10.2215/CJN.05811108. PMC 2666438. PMID 19339425.
- "Archived copy". Archived from the original on 2015-02-06. Retrieved 2015-02-06.CS1 maint: Archived copy as title (link)[unreliable medical source?]
- Biyani CS, Cartledge JJ (2006). "Cystinuria—Diagnosis and Management" (PDF). EAU-EBU Update Series. 4 (5): 175–83. doi:10.1016/j.eeus.2006.06.001. ISSN 1871-2592.
- Ahmed, K.; Dasgupta, P.; Khan, M. S. (2006). "Cystine calculi: Challenging group of stones". Postgraduate Medical Journal. 82 (974): 799–801. doi:10.1136/pgmj.2005.044156. PMC 2653923. PMID 17148700.
- Online Mendelian Inheritance in Man (OMIM) 220100
- Ahmed, Kamran; Khan, Mohammad Shamim; Thomas, Kay; Challacombe, Ben; Bultitude, Matthew; Glass, Jonathan; Tiptaft, Richard; Dasgupta, Prokar (2008). "Management of Cystinuric Patients: An Observational, Retrospective, Single-Centre Analysis". Urologia Internationalis. 80 (2): 141–4. doi:10.1159/000112603. PMID 18362482.
- Joly, Dominique; Rieu, Philippe; méJean, Arnaud; Gagnadoux, Marie-France; Daudon, Michel; Jungers, P. (1999). "Treatment of cystinuria". Pediatric Nephrology. 13 (9): 945–50. doi:10.1007/s004670050736. PMID 10603157.
- Zee, Tiffany; Bose, Neelanjan; Zee, Jarcy; Beck, Jennifer N.; Yang, See; Parihar, Jaspreet; Yang, Min; Damodar, Sruthi; Hall, David (March 2017). "α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria". Nature Medicine. 23 (3): 288–290. doi:10.1038/nm.4280. ISSN 1078-8956.
- "Alpha-lipoic acid prevents kidney stones in mouse model of rare genetic disease: Research leads to clinical trial for cystinuria". ScienceDaily. Retrieved 2017-07-09.
- D Bannasch; PS Henthorn (2009). "Changing Paradigms in Diagnosis of Inherited Defects Associated with Uroliths". Veterinary Clinics of North America: Small Animal Practice. 39 (1): 111–125. doi:10.1016/j.cvsm.2008.09.006. PMC 2628803. PMID 19038654.